Photodynamic therapy of ascites tumours within the peritoneal cavity. by Tochner, Z. et al.
Br. J. Cancer (1986), 53, 733-736
Photodynamic therapy of ascites tumours within the
peritoneal cavity
Z. Tochner3, J.B. Mitchell', P. Smith2, F. Harrington', E. Glatstein', D. Russo'
& A. Russo'
'Experimental Phototherapy Section, Radiation Oncology Branch, Clinical Oncology Program, National
Cancer Institute, National Institutes ofHealth (B3-B69, Building #10); 2Biomedical Engineering and
Instrumentation Branch, Division ofResearch Services, National Institutes ofHealth, 9000 Rockville Pike,
Bethesda, Maryland 20892, USA; 3Hadasha Hospital, Jerusalem, Israel.
Summary A murine ascites tumour was treated with intraperitoneal haematoporphyrin derivative (HPD) and
laser light (lOmW, 514nm, Argon laser). HPD was given intraperitoneally 2 hours before 16 minute laser
treatment. Uptake studies 2 hours after HPD injection showed 5-12 fold greater concentration of HPD in
tumour cells than in 4 different normal tissues. A total of four HPD/laser treatments, given at 2 day intervals,
resulted in 100% complete response; the cure rate was 85%. This study illustrates the effective use of
intraperitoneal photodynamic therapy and opens the possibility of exploring different sensitizers, excitation
wavelengths, and delivery systems in the treatment of human ascites tumours.
Single and multiple modality programmes have
been used to treat human ovarian carcinoma
(Young et al., 1982; Ozols et al., 1984a,b). At
present, ovarian carcinoma is the leading cause of
gynaecologic cancer death in the USA with more
than 11,000 women dying per year (Young et al.,
1982). Intraperitoneal drug therapy for ovarian
cancer is experimentally interesting, yet, even
though the results have been suggestive, no clear
therapeutic advantage has been demonstrated. The
combination of HPD injection and subsequent light
exposure, referred to as photodynamic therapy
(PDT) (Kessel, 1984), has been a successful
treatment modality for superficial malignancies of
the skin (Vincent et al., 1981), trachea and
bronchus (Hayata et al., 1982; Cortese & Kinsey,
1982), eye (Gomer et al., 1983), bladder (Kelly &
Snell, 1976), and alimentary tract (Douglass et al.,
1981). Previously, we illustrated the feasibility of
using PDT for ascites tumours (Tochner et al.,
1985); now, we demonstrate that PDT can be
extremely effective in a murine model and suggest it
may have a role in the treatment of human ascites
tumours.
Materials and methods
C3HeB/FeJ female mice (Jackson Laboratories, Bar
Harbor, Maine, USA) were injected i.p. with an
ascitic malignant teratoma that had previously
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originated spontaneously in the C3H strain (Fekete
& Ferringno, 1952). This tumour rarely metastasizes
out of the peritoneum, the peritoneal deposits are
<3mm in diameter, and a 2-3 x 105 cells i.p.
injection causes death within 23-25 days. Eight
days after tumour transplantation all mice had
evidence of malignant ascites and weighed -2g
more than control mice. On the 8th day, 2h before
laser treatment, HPD (Photofrin Medical Inc.,
Rariton, NJ, USA) in 0.25ml aqueous solution
was injected i.p. (10mgkg-1). Twenty mice
received PDT at 2 day intervals to a total of 4
treatments. Each treatment required one peritoneal
puncture for fibre placement. The tip of the fibre
was inserted 0.5cm mid abdominally into the
peritoneum and directed to the periphery of octants
(three in the upper abdomen, three in the lower
abdomen, one in the mid left abdomen, and one in
the mid right abdomen). Normal saline (2ml) was
injected i.p. immediately before the second, third,
and fourth laser treatments to enhance light propa-
gation. Laser light (514nm; Lexel Model 65 Argon
ion laser, Palo Alto, CA, USA), at a power level of
10mW as measured at the fibre tip (Spectra-Physics
Meter, Model 401, Spectra-Physics Inc., Mt View,
CA, USA), was directed into the peritoneum via a
single 125 micron optical fibre (Corning Glass
Company, Corning, NY, USA). The fibre was
housed within a 15cm sleeve of 30 gauge stainless
steel hypodermic tubing, and the tubing was
positioned through a mid-abdominal peritoneal
puncture into the designated octants. The tip of
the fibre was flat and non-scattering, and the
514nm light's angle of divergence was minimal.
Each octant was treated for 2min; total treatment
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time was 16min. To minimize sepsis, all mice were
injected after each treatment with 0.2ml of normal
saline containing 1500U of aqueous penicillin.
Control mice were treated with either HPD or laser
light alone. All mice were inspected and weighed
daily. In the absence of a known assay for total
HPD ether, the putative sensitizing agent,
intracellular HPD levels were assessed by
determining the total porphyrin concentration by a
modification of Winkelman's method (Winkelman
& Rasmussen-Taxdal, 1960). In brief, tumour cells
were removed from the peritoneal cavity, rinsed
twice with PBS, sonicated, and suspended in an
acetic acid/sodium acetate solution. The suspension
was centrifuged (104RCF,4°C, 10min), the super-
natant was removed, the pellet was extracted with
diethyl ether, the ether layer was extracted with an
aqueous HCI solution, and the aqueous HCI layer
was assessed by absorbance (400nm) and fluo-
rescence (excitation 395/ emission 609nm) spectro-
scopy. Protein determinations were done by the
dye-binding method (Bradford 1976).
Results
HPD levels were measured in tumour and normal
tissues at various times after i.p. injection (Table I).
HPD concentrations were high in tumour cells after
2h and remained elevated for 72h. Both kidney
and liver contained substantial levels of porphyrin,
corroborating previous studies (Douglass et al.,
1981). Figure 1 shows the weight gain charac-
teristics of tumour-bearing mice after PDT; the
weights of the treated mice fell below that of
Table I HPD uptake in tumour and selected normal
tissues
Time
(h) Tumour Liver Kidney Muscle Bowel
2 1414+195 270+36 119+14 142+35 141+35
(10) (10) (10) (10) (10)
24 209+51 343+63 - 62+25 44+15
(11) (10) (11) (2)
48 98+33 292+30 71+12 38+ 10 116+33
(5) (10) (10) (10) (7)
72 34+8 95+ 15 11+2 6+1 NF
(9) (4) (I11) (10) (10)
This represents the HPD concentration (ngmg 1
protein) + s.e.m. determined in the tissues listed above
(NF means none found). The time is hours after injection
of i.p. HPD. Numbers in parentheses denote number of
mice used in that determination.
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Figure 1 Mean body weight of mice injected with
2 x 105 tumour cells on day 0. Each group consisted of
20 mice. Control groups: (0), laser light alone; (A),
tumour alone, no PDT treatment; (*), HPD alone.
All mice within these groups died within 25 days. The
weight of the mice within each group differed <2g
from the mean. (V) represent the weight of mice that
were not injected with tumour cells and (0) represent
mice that were treated with PDT, as described in the
text, on days 8, 10, 12, and 14 after tumour injection.
control mice. Since mice did not lose weight after
the second, third, and fourth treatment, the initial
weight loss probably represented the weight of
ascitic tumour. After mice were treated and
apparently cured, their weights quickly returned to
that of controls. Tumour-bearing mice treated with
only laser or HPD continued to show tumour
growth as evaluated by accumulation of ascites. All
controls died within 25 days of tumour transplan-
tation. Figure 2 shows survival results for mice
treated with PDT: 17 of 20 mice (85%) were cured.
Although not shown, these mice were free of
disease at 11 months. Three of 20 mice (15%) died
as a direct result of tumour spreading into the
subcutaneous space along the track of the laser
probe. Once the tumour began to grow
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Figure 2 Survival of mice after injection of 2x 105
tumour cells/mouse on day 0. Each group contained
20 mice. Closed symbols as in Figure 1. (Q) represent
mice treated on days 8, 10, 12, and 14 with PDT.PHOTOTHERAPY OF MURINE ASCITIC TUMOURS 735
subcutaneously, mice died quickly. Figure 2 also
illustrates that there were no early deaths from
treatment-related bowel perforation or sepsis; either
complication is a major concern of percutaneous
puncture and probing of the abdominal cavity
(Tochner et al., 1985). Five mice that had been
cured of their initial tumour by PDT were
reinjected with 2 x 105 tumour cells. Once again,
these mice developed tumour, and the rate of
tumour growth was the same as the initial tumour
growth. This control was performed to establish
that the peritoneum had not been damaged to the
extent of compromising tumour growth by some
nutritional mechanism.
Discussion
The biological characteristics of this particular
tumour (ascitic peritoneal spread, tumour deposits
<3mm, and only slight penetration into the
diaphragm (Fekete & Ferringno, 1952)) provides a
model to illustrate that tumour spread into pockets
of the peritoneum can be effectively treated by
PDT. Since diaphragmatic and serosal surface im-
plantations are frequent sites of initial intra-
peritoneal carcinomatosis in humans (Young et al.,
1982), PDT may have a clinical role. Moreover, in
this study, less penetrating 514nm laser light was
used rather than the usual 630nm reported for
most HPD based PDT studies. There may be an
advantage to treatment at 514nm light for non-
solid tumours (Bellnier et al., 1985): depth of light
penetration into the tumour is of less importance,
and HPD absorbance is three times greater at 514
than at 630nm. Greater light absorbance should
result in greater singlet oxygen production and
better tumour kill. Normally, tumours are treated
48-72h after HPD injection. The rationale for
delayed laser treatment is that at 48-72h there is a
greater differential retention of HPD in solid
tumours than normal tissue (Dougherty et al.,
1978); however, we treated tumours earlier, 2h after
HPD i.p. injection, because in our model there is
excellent early HPD uptake by the ascites tumour
cells. Were tumour nodules within the peritoneal
cavity larger, more conventional protocols may
have been required (Kessel, 1984).
Previously, we have shown the feasibility of PDT
for intraperitoneal tumours (Tochner et al., 1985).
In this study, we have achieved an 85% cure by
increasing the frequency and number of treatments.
There is one previous study which allows com-
parison of PDT to relative effective chemotherapy
(Ozols et al., 1979). In that study, the same murine
tumour model was used, and treatment by i.p.
adriamycin at different times after tumour
transplantation was investigated. The authors
achieved a 70% cure in one subset, but only if
adriamycin injections were made as early as 48h
after tumour transfer. If they waited longer, when
the tumour burden was greater - as we did in this
study - less than 20% cure was achieved. Frequent
treatments could not be used because of the
inherent systemic toxicity of adriamycin. We have
achieved an 85% cure with fractionated treatments,
and further, if tumour seeding had not occurred
along the laser fibre track, it is possible that a
100% cure would have been achieved. Tumour
spreading into the subcutaneous space is a technical
complication that may be better studied in larger
animals. Although our results of high percentage of
cures for an ascites tumour are promising, the
treatment of human ovarian carcinoma, which
frequently involves large tumour deposits (>3mm),
may not respond to treatment with 514nm light.
The efficacy of treating such tumours with greater
tissue-penetrating, longer wavelength light needs to
be studied. We are currently studying longer wave-
length absorbing sensitizers for treatment of ascites
tumours and intraperitoneal solid tumours. At
present, we conclude from the work presented in
this study that (a) HPD based PDT appears to be
more effective than i.p. chemotherapy for ascites
tumours, and (b) PDT should be studied in larger
animals with the ultimate aim of evaluating its
efficacy for primary or adjuvant treatment of
human malignant ascites tumours such as ovarian
carcinoma.
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